- The European Menopause and Andropause Society (EMAS) and the International Gynecologic Cancer Society (IGCS) have released a position statement on managing menopausal symptoms after gynecological cancer.
Why this matters
- 1.3 million new gynecological cancers are diagnosed worldwide each year.
- Gynecological cancer treatment can result in surgical menopause even as hormone receptors are intact and with use of antiestrogenic therapies.
- Management by tumor type:
- Endometrial cancer: women with low-grade, early-stage endometrial cancer may consider topical or systemic estrogens.
- Uterine sarcoma: if hormonal dependent, avoid hormone replacement therapy (HRT).
- Ovarian, fallopian tube, and stromal cancer: limited evidence that HRT does not appear to cause harm with nonserous epithelial ovarian cancer and germ cell tumors; use caution with serous and granulosa cell tumors.
- Cervical, vaginal, and vulvar cancer: HRT is not contraindicated.
- Systematic review and position statement from EMAS and IGCS.
- Funding: None.
- Limitations related to the limitations of original studies.
- Paucity of data for some cases makes recommendations difficult.